The ONE report includes deals for five vaccines that have been approved, or are set to gain regulatory approval in the first half of 2021 after they were deemed safe and effective in clinical trials: Pfizer-BioNTech, Moderna, Oxford-AstraZeneca, Janssen (J&J), and Novavax.
It found that the UK was on track to see more than 113 million spare doses of 247 million of these five candidates it has access to. Meanwhile the United States will see a surplus of 453 million and the EU roughly 464 million.
To date, a fraction of the doses purchased by governments have been administered, even in wealthy countries. Some 16.4 million people in the UK have had their first dose, while 573,724 have had two.
Supply has also been an issue and, while vaccine manufacturers race to ramp up production, global shortages are likely to persist.
UK ministers, including the Health Secretary Matt Hancock, have suggested Britain will complete domestic rollout efforts before donating doses internationally.
“We definitely want to vaccinate our own population first,” Clive Dix, head of UK Vaccine Taskforce, added this week. “It would be a bit weird to have people still waiting and giving the vaccines to others.”
Protect yourself and your family by learning more about Global Health Security